Notable Labs

Notable Labs EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Notable Labs (NTBLQ) as of Nov 8, 2026 is 55.38 %. In the previous year, Year-over-Year EBITDA Growth was -9.50 % — a change of -682.97% (higher).

EBITDA Growth YoY

55.38 %

YoY

-682.97%

Last updated:

Year-over-Year EBITDA Growth of Notable Labs is 2023 55.38 % . Year-over-Year EBITDA Growth of Notable Labs was 2022 -9.50 % . It decreases by -682.97% higher compared to the previous year.

The Notable Labs EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2016
-9.49 USD
Jan 1, 2017
34.98 USD
Jan 1, 2018
-102.38 USD
Jan 1, 2019
5.51 USD
Jan 1, 2020
-21.91 USD
Jan 1, 2021
-22.55 USD
Jan 1, 2022
-9.50 USD
Jan 1, 2023
55.38 USD
The Notable Labs EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
55.38 %-682.97%
-9.50 %-57.87%
-22.55 %+2.91%
-21.91 %-497.98%
5.51 %-105.38%
-102.38 %-392.65%
34.98 %-468.59%
-9.49 %+1,163.24%
-0.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Year-over-Year EBITDA Growth of Notable Labs is 55.38 % in 2023.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Notable Labs since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Notable Labs

All Key Metrics — Notable Labs